|
|
5-day change | 1st Jan Change | ||
|
1,037,000.00 KRW |
+0.19% | +3.70% | +9.27% | |
April 28, 2025 at 10:32 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Samsung Biologics Wins KRW737.3 Billion Biologics CMO Contract From US Pharmaceutical Firm |
10:32pm |
MT |
|
Samsung Biologics Co Wins 737 Billion Won Contract |
Apr. 27 |
RE |
|
Samsung Biologics’ Net Attributable Income Jumps Over 100% in Q1 |
Apr. 23 |
MT |
|
South Korean Shares Marginally Rise on Potential End of US-China Tariff Tit-for-Tat |
Apr. 20 |
MT |
|
South Korean Shares Gain Marginally as Investors Shift Focus on Korea-US Trade Negotiations |
Apr. 16 |
MT |
|
South Korean shares rise as automakers jump on US tariff exemption hopes |
Apr. 15 |
RE |
|
S.Korean shares rise as automakers jump on tariff exemption hope; drugmakers fall |
Apr. 14 |
RE |
|
South Korean Shares Open Mixed as Trump Administration Eyes Tariffs on Pharma, Chips |
Apr. 14 |
MT |
|
Trump Signals Incoming Tariffs on Imported Drugs, Move Aims to Relocate Pharma Production to US |
Apr. 09 |
MT |
|
Samsung Biologics Co.,Ltd.(KOSE:A207940) added to S&P International 700 |
Mar. 23 |
CI |
|
Samsung Biologics Co.,Ltd.(KOSE:A207940) added to S&P Global 1200 |
Mar. 23 |
CI |
|
Nomura Upgrades Samsung Biologics to Buy From Neutral, Adjusts Price Target to KRW1.4 Million From KRW840,000 |
Mar. 17 |
MT |
|
C2N Diagnostics, LLC announced that it has received $10 million in funding from Samsung C&T Corporation, Samsung Biologics Co.,Ltd., Samsungbioepis Co,.Ltd, Samsung Venture Investment Corporation |
Mar. 12 |
CI |
|
Apogee Therapeutics, Inc. Enters into Master Services Agreement with Samsung Biologics Co., Ltd |
Mar. 11 |
CI |
|
South Korean shares fall as Nvidia-supplier SK Hynix drags |
Feb. 26 |
RE |
|
Samsung Bioepis Launches Stelara Biosimilar Pyzchiva in US |
Feb. 25 |
MT |
|
Samsung Biologics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 25 |
CI |
|
South Korean shares snap seven-day rally as chip, automakers fall |
Feb. 20 |
RE |
|
South Korean shares drop as traders gauge Trump’s latest tariff threat |
Feb. 19 |
RE |
|
S.Korean shares end 1% higher as exporters rally on tariff optimism |
Feb. 13 |
RE |
|
S.Korean shares end at 3-week high on tariff optimism despite Trump’s comments |
Feb. 11 |
RE |
|
South Korean shares rise 1% on tariff optimism despite Trump’s comments |
Feb. 10 |
RE |
|
Samsung Chairman Jay Y. Lee Cleared of Accounting Fraud and Stock Manipulation |
Feb. 04 |
MT |
|
The legal challenges faced by Samsung chief Jay Y Lee |
Feb. 03 |
RE |
|
Samsung chief Jay Y. Lee found not guilty in merger case |
Feb. 03 |
RE |
A207940: Dynamic Chart
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in the production of antibody drugs. The Company operates through two segments. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides biopharmaceutical contract manufacturing and cell line development services. The Biopharmaceutical Development and Commercialization segment primarily engages in the development and commercialization of biosimilars.
More about the company
Buy
Last Close Price
1,037,000.00KRW
Average target price
1,313,375.00KRW
Spread / Average Target
+26.65%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
